Page 3 - Dr Reddys Laboratories Ltd News
Pharma cos brace for soft Q4; US drag persists; domestic growth cushions
Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements
 "Pharma cos brace for soft Q4; US drag persists; domestic growth cushions")
Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on
Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.
 "Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on")
Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?
Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.
 "Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?")
Axis Bank, Voda Idea: 28 Nifty 500 stocks reclaim 200-DMA today; full list
Among others Dr. Reddy's, Apollo Hospitals, M&M Finance, Muthoot Finance, Tata Power, Balrampur Chini and Sammaan Capital soared up to 20% from recent lows to cross the long-term average, shows data.
 "Axis Bank, Voda Idea: 28 Nifty 500 stocks reclaim 200-DMA today; full list")